MetaVia Inc.
MTVA
Helyezés a részvények között
#33010
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Részvényárfolyam
$1.24
Piaci kapitalizáció
$8.17M
Változás (1 nap)
-1.59%
Változás (1 év)
-23.93%
Ország
US
Kereskedés MetaVia Inc. (MTVA)
Kategória
Healthcare
Piaci kapitalizációja MetaVia Inc.(MTVA)
Piaci kapitalizáció: $8.17M
October 2026-ban a MetaVia Inc. piaci kapitalizációja $8.17M. Ez alapján a MetaVia Inc. a világ 33010th legértékesebb vállalata a piaci kapitalizáció szerint. A piaci kapitalizáció egy tőzsdén jegyzett vállalat összes részvényének piaci értéke, amelyet gyakran használnak a vállalat értékének mérésére.
MetaVia Inc. piaci kapitalizációjának története 2016 és 2026 között
MTVA összehasonlítva az 5 legnépszerűbb stocks
